XML 80 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE (Details 2) (USD $)
 3 Months Ended 6 Months Ended 203 Months Ended 0 Months Ended 3 Months Ended 12 Months Ended 0 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Apr. 03, 2013
Celgene Corporation
patent
Dec. 14, 2012
Aspire Capital Fund, LLC
Common stock
Mar. 31, 2013
Aspire Capital Fund, LLC
Common stock
Dec. 31, 2012
Aspire Capital Fund, LLC
Common stock
Dec. 14, 2012
Aspire Capital Fund, LLC
Maximum
Common stock
Mar. 22, 2012
Economic Rights
Jun. 30, 2013
Economic Rights
Dec. 31, 2012
Economic Rights
Apr. 30, 2013
Economic Rights
Celgene Corporation
Mar. 31, 2013
Economic Rights
Celgene Corporation
Feb. 28, 2007
Warrants
Jun. 30, 2013
Warrants
Jun. 30, 2012
Warrants
Jun. 30, 2013
Warrants
Jun. 30, 2012
Warrants
Dec. 31, 2012
Warrants
Jun. 30, 2013
Warrants
Maximum
Dec. 31, 2012
Warrants
Maximum
Reconciliation of the beginning and ending balance of Level 3 inputs                                            
Balance at the beginning of the period                     $ 1,140,000                      
Change in valuation of liability                     (570,000)         0 8,000 0 50,000      
Movement of valuation of liability from Level 3 to Level 2                     (550,000)                      
Balance at the end of the period                     20,000                      
Number of shares issued under purchase agreement           158,982 650,000                              
Purchase price for shares issued under purchase agreement           1,000,000 3,400,000                              
Additional shares committed for sale under agreement                 1,455,787                          
Period of common stock purchase agreement           2 years                                
Common stock purchase agreement, additional amount committed                 19,000,000                          
Stock issued in lieu of commitment fee           74,548                                
Stock purchase agreement       423,000       400,000                            
Amount to be paid as percentage of future litigation settlement amount received                   10.00%                        
Number of patents in litigation sold under the definitive agreement         4                                  
One time payment received under the definitive agreement         5,500,000                                  
Amount paid to the holders of liability                         600,000                  
Fair value of the liability                       1,100,000                    
Change in fair value of the derivative (146,000) (570,000) (90,000) (547,000)             600,000                      
Actual amount owed as a percentage of one-time payment received                           10.00%                
Warrants Liability                                            
Fair value of the warrants                             $ 6,800,000 $ 0   $ 0   $ 0    
Risk free interest rate (as a percent)                             4.68%              
Expected volatility (as a percent)                             85.00%              
Expected dividend yield (as a percent)                             0.00%              
Contractual life                             7 years              
Expected term                                         1 year 1 year